5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates

Several big pharma companies have reported their first-quarter results so far, demonstrating recovery in sales during the quarter. Sales of key drugs continued to recover from the adverse impacts of COVID-related disruptions. The performance of non-COVID vaccines was mixed. Renewed travel during the past few months boosted sales of several travel vaccines. However, COVID-19 vaccine prioritization during the first quarter hurt certain flu vaccine sales. Companies marketing COVID-19 therapies benefited the most during the first quarter with significant sales from their therapies.